Sol-Gel Technologies Operating Income 2016-2023 | SLGL
Sol-Gel Technologies operating income from 2016 to 2023. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Sol-Gel Technologies Annual Operating Income
(Millions of US $) |
| 2023 |
$-29 |
| 2022 |
$-16 |
| 2021 |
$3 |
| 2020 |
$-30 |
| 2019 |
$-26 |
| 2018 |
$-34 |
| 2017 |
$-32 |
| 2016 |
$-21 |
| 2015 |
$-10 |
Sol-Gel Technologies Quarterly Operating Income
(Millions of US $) |
| 2023-12-31 |
$-6 |
| 2023-09-30 |
$-6 |
| 2023-06-30 |
$-7 |
| 2023-03-31 |
$-11 |
| 2022-12-31 |
$-6 |
| 2022-09-30 |
$-4 |
| 2022-06-30 |
$-0 |
| 2022-03-31 |
$-6 |
| 2021-12-31 |
$14 |
| 2021-09-30 |
$1 |
| 2021-06-30 |
$-8 |
| 2021-03-31 |
$-4 |
| 2020-12-31 |
$-7 |
| 2020-09-30 |
$-9 |
| 2020-06-30 |
$-8 |
| 2020-03-31 |
$-7 |
| 2019-12-31 |
$-7 |
| 2019-09-30 |
$-8 |
| 2019-06-30 |
$-5 |
| 2019-03-31 |
$-6 |
| 2018-12-31 |
$-12 |
| 2018-09-30 |
$-8 |
| 2018-06-30 |
$-7 |
| 2018-03-31 |
$-6 |
| 2017-12-31 |
|
| 2017-09-30 |
|
| 2017-06-30 |
$-6 |
| 2016-12-31 |
|
| 2015-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.026B |
$0.002B |
|
Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel.
|
